Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, Montie J, Sarkar FH, Shah RB, Hussain M.
Friedman J, et al. Among authors: wood d.
J Urol. 2008 Mar;179(3):911-5; discussion 915-6. doi: 10.1016/j.juro.2007.10.064. Epub 2008 Jan 22.
J Urol. 2008.
PMID: 18207190
Free PMC article.